Scarica l'app Stockscreener
8.00
4.88%
-0.41
Dopo l'orario di chiusura:
7.99
-0.010
-0.12%
Precedente Chiudi:
$8.41
Aprire:
$8.43
Volume 24 ore:
782.12K
Relative Volume:
0.57
Capitalizzazione di mercato:
$713.34M
Reddito:
$380.79M
Utile/perdita netta:
$49.27M
Rapporto P/E:
11.43
EPS:
0.7
Flusso di cassa netto:
$10.68M
1 W Prestazione:
+4.71%
1M Prestazione:
-1.48%
6M Prestazione:
+115.05%
1 anno Prestazione:
+270.37%
Intervallo 1D:
$7.92
$8.4712
Intervallo di 1 settimana:
$7.605
$8.49
Portata 52W:
$2.045
$8.72
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Industria
Telefono
617-683-0917
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Confronta AMLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
8.00 | 749.90M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Pharmaceuticals’ Promising Earnings Call Highlights - MSN
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attention2025 Historical Comparison & Reliable Volume Spike Trade Alerts - sundaytimes.kr
Drawdown in Amylyx Pharmaceuticals Inc. May Be Nearing EndMarket Risk Summary & Weekly Stock Breakout Alerts - metal.it
Amylyx Pharmaceuticals Inc. Inches Above Key Support — Safe to Hold2025 Technical Patterns & Real-Time Market Sentiment Alerts - sundaytimes.kr
Can Amylyx Pharmaceuticals Inc. ride the EV waveExit Point & Risk Managed Investment Entry Signals - newsyoung.net
Will Amylyx Pharmaceuticals Inc. benefit from rising consumer demandTrend Confirmation Stock Picks - thegnnews.com
Will Breakout in Amylyx Pharmaceuticals Inc. Sustain Through Next WeekAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial - MSN
Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline - MSN
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amylyx Reports Q2 EPS of 46c, Meets Consensus Estimate - AInvest
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements - TipRanks
Amylyx Pharmaceuticals Q2 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals: Progress in Trials and Financials - TipRanks
Amylyx Pharmaceuticals: Strategic Progress in Neurodegenerative Therapies and the Path to Long-Term Value - AInvest
Amylyx in 2026: A High-Risk, High-Reward Biotech Catalyst Play - AInvest
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - Yahoo Finance
Amylyx Pharmaceuticals' Q2 2025: Key Contradictions in PBH Patient Estimates, Trial Analysis, and Market Opportunities - AInvest
Amylyx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Game-Changer for Post-Bariatric Hypoglycemia - TipRanks
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential - TipRanks
Amylyx (AMLX) Q2 Net Loss Narrows 43% - Nasdaq
Transcript : Amylyx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Amylyx Pharma Q2 net loss wider than expected as R&D costs increase - TradingView
Amylyx Pharmaceuticals: A Biotech Undervalued by Momentum and Milestones - AInvest
Amylyx Pharmaceuticals Advances Avexitide Study for Post-Bariatric Hypoglycemia - TipRanks
Amylyx Pharmaceuticals’ ALS Study: A Potential Game-Changer for Investors - TipRanks
Amylyx Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
After strategic reset, Amylyx downsizes, moves Cambridge HQ - The Business Journals
How volatile is Amylyx Pharmaceuticals Inc. stock compared to the marketAchieve exceptional returns with expert guidance - Jammu Links News
What is the dividend policy of Amylyx Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What are analysts’ price targets for Amylyx Pharmaceuticals Inc. in the next 12 monthsSkyrocketing profit margins - Jammu Links News
What are the latest earnings results for Amylyx Pharmaceuticals Inc.Build wealth with long-term growth strategies - Jammu Links News
What analysts say about Amylyx Pharmaceuticals Inc. stockBuild a portfolio that delivers consistent profits - Jammu Links News
Should I hold or sell Amylyx Pharmaceuticals Inc. stock in 2025Fastest return on investment - Jammu Links News
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyBuild wealth faster with consistent investment plans - Jammu Links News
What are Amylyx Pharmaceuticals Inc. company’s key revenue driversBreakthrough wealth creation - Jammu Links News
What catalysts could drive Amylyx Pharmaceuticals Inc. stock higher in 2025Discover high-impact stocks for growth - Jammu Links News
Amylyx Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Amylyx Pharmaceuticals Inc. stockMaximize your gains with expert trading tips - Jammu Links News
When is Amylyx Pharmaceuticals Inc. stock expected to show significant growthUnlock exclusive stock market forecasts - Jammu Links News
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX): Is Breakeven Near? - 富途牛牛
How many analysts rate Amylyx Pharmaceuticals Inc. as a “Buy”Unlock expert insights for smarter investing - Jammu Links News
Does Amylyx Pharmaceuticals Inc. stock perform well during market downturnsTransform your portfolio with high-yield stocks - Jammu Links News
Is it the right time to buy Amylyx Pharmaceuticals Inc. stockTriple-digit return opportunities - Jammu Links News
In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review - Physician's Weekly
What is the risk reward ratio of investing in Amylyx Pharmaceuticals Inc. stockChart Pattern Updates For Fast Growth - Jammu Links News
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amylyx Pharmaceuticals Inc Azioni (AMLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Aug 12 '25 |
Sale |
8.07 |
15,000 |
121,102 |
171,969 |
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):